Want to join the conversation?
In 4Q15, $STJ posted sales of $580MM in its largest segment Cardiac Rhythm Management, down 15% from 4Q14. Atrial Fibrillation product sales fell 2% to $276MM. Cardiovascular sales fell 6% to $327MM while Neuromodulation product sales rose 3% to $128MM.
$NFLX a monster move, going up. Expect making some money on Monday.
$AMD down more than 6% even after posting above consensus third quarter results.
$MCD stock rose more than 2% after it posted better than expected 3Q16 results, driven by global same-store sales growth. Meanwhile, earnings and revenue were lower than last year, hurt by refranchising efforts.